News and Trends 22 Jul 2022Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma On this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach, and Eric Moessinger, both partners at +ND Capital; and Louise Modis, chief scientific officer at Mogrify. Poolbeg Pharma gets approval for severe influenza drug trial Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority […] July 22, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2022 Poolbeg Pharma gets approval for severe influenza drug trial Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority approval to commence its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment for severe influenza. Clinical trial activities will formally commence on […] July 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2022 Additional funding for trial to study drug targeting lung immunity in elderly patients Lung immunity in the elderly will be the subject of a controlled clinical trial after receiving clearance to go ahead from Health Canada. Qu Biologics will receive additional funding to launch the trial for the restoration of innate immune function – the defense system humans are born with. Qu, a private clinical stage biopharmaceuticals company […] July 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 SINOVAC starts influenza vaccine trial in Chile Sinovac Biotech Ltd., a provider of biopharmaceutical products in China, has initiated a phase III clinical trial for SINOVAC’s inactivated quadrivalent influenza vaccine in Chile through a collaboration with the Pontificia Universidad Católica de Chile. SINOVAC said the results aim to provide scientific evidence to support its influenza vaccine immunogenicity and protection capacity. This clinical […] July 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Osivax gets €10M influenza vaccine grant A grant of €10 million ($10.5 million) has been secured by pharmaceutical company Osivax to support a vaccine against influenza. The biopharma company develops vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases. It announced today (June 23) that it has secured the funds from Bpifrance to support the further clinical development […] June 23, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email